Takahiro Wakasaki

Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab

Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda et al. · Oral Oncology · 2019 · 95 citations · Full text

Medicine, Immunology, Oncology +13

Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer

Ryuji Yasumatsu, Takahiro Wakasaki, Kazuki Hashimoto et al. · Head & Neck · 2019 · 58 citations

Medicine, Oncology, Pharmacology +14

Chemoprevention of Head and Neck Cancer by Green Tea Extract: EGCG—The Role of EGFR Signaling and “Lipid Raft”

Muneyuki Masuda, Takahiro Wakasaki, Satoshi Toh et al. · Journal of Oncology · 2011 · 50 citations · Full text

Medicine, Oncology, Pharmacology +15

T Cell Leukemia/Lymphoma 1 and Galectin-1 Regulate Survival/Cell Death Pathways in Human Naive and IgM+ Memory B Cells through Altering Balances in Bcl-2 Family Proteins

Hiroaki Niiro, Mariko Masui, Goichi Yoshimoto et al. · The Journal of Immunology · 2009 · 49 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma

Takahiro Wakasaki, Ryuji Yasumatsu, Ryutaro Uchi et al. · Auris Nasus Larynx · 2019 · 41 citations

Medicine, Oncology, Chemotherapy +8